gurufocus.com · 29 jun

AbbVie Receives Positive CHMP Opinion for Upadacitinib (RINVOQ®) for the Treatment of Adults and Adolescents with Severe Alopecia Areata

AbbVie Receives Positive CHMP Opinion for Upadacitinib (RINVOQÂ) for the Treatment of Adults and Adolescents with Severe Alopecia Areata

gurufocus.com · 26 jun

Incyte Announces Positive CHMP Opinion for Opzelura® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis

Incyte (Nasdaq: INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positi

globenewswire.com · 23 jun

AD Mortgage Survey Finds Growing Demand for Non-QM Lending Among Brokers

FORT LAUDERDALE, Fla., June 23, 2026 (GLOBE NEWSWIRE) -- AD Mortgage , a leading wholesale lender in the United States, today released findings from its latest broker survey,  Non-QM Fuels Mortgage Industry in 2026  revealing strong momentum for Non-QM lending across the mortgage industry.

globenewswire.com · 18 jun

Alaris Equity Partners Income Trust Declares Q2 Distribution

NOT FOR DISTRIBUTION IN THE UNITED STATES. FAILURE TO COMPLY WITH THIS RESTRICTION MAY CONSTITUTE A VIOLATION OF UNITED STATES SECURITIES LAW.

globenewswire.com · 18 jun

Derm-Biome's DB-006 Demonstrates Superior Efficacy in Preclinical Atopic Dermatitis Study: Reduces Itch, Inflammation, and IgE Levels, Outperforms Leading Topical Drugs

VANCOUVER, British Columbia, June 18, 2026 (GLOBE NEWSWIRE) -- Derm-Biome Pharmaceuticals, Inc., a Vancouver-based biopharmaceutical company focused on skin health and longevity, today announced positive preclinical results for its novel small molecule, DB-006. The compound demonstrated high efficacy in treating atopic dermatitis (AD), significantly reducing key disease drivers, including pruritus (itch), epithelial thickening, inflammation, and immunoglobulin E (IgE) levels.

businesswire.com · 17 jun

Oligomerix Awarded $1.9 M NIH Phase II SBIR Fast-Track Grant to Conduct Safety Studies Required for Clinical Studies of OLX-07010 in Alzheimer's Patients

BRONX, N.Y.--(BUSINESS WIRE)-- #Alzheimers--Oligomerix, Inc., a privately held clinical stage company pioneering the development of oral, small molecule therapeutics targeting Alzheimer's (AD) and rare neurodegenerative diseases, announced an NIH Fast Track Phase II award of $1.9 million from the National Institute on Aging of the National Institutes of Health. This grant supports clinical development of OLX-07010, an orally administered investigational drug, targeting pathological tau aggregates that drive.

prnewswire.com · 10 jun

Elixiron Immunotherapeutics Reports Positive Phase 2 Interim Results for Enrupatinib: Evidence of Neuroinflammation Reduction and Early Cognitive Benefit in Alzheimer's Disease

CAMBRIDGE, Mass. and TAIPEI, June 10, 2026 /PRNewswire/ -- Elixiron Immunotherapeutics (TPEx: 7871), a clinical-stage biopharmaceutical company pioneering precision immunotherapy for neurodegenerative and autoimmune diseases, today announced positive interim results from its ongoing Phase 2 proof-of-concept study of enrupatinib (EI-1071), a brain-penetrant colony-stimulating factor 1 receptor (CSF-1R) inhibitor designed to modulate neuroinflammation in Alzheimer's disease (AD).

gurufocus.com · 10 jun

Is It Too Late to Buy Array Digital Infrastructure Inc (AD) After 3.1% Rally? GF Value Says Undervalued

On June 10, 2026, Array Digital Infrastructure Inc (AD) shares rose 3.1% to a current price of $52.35. The stock has fluctuated within a 52-week range of $44.03